What You Should Know:
– Tempus, a leader in artificial intelligence and precision medicine, announced a groundbreaking data contribution to the National Cancer Institute (NCI) today.
– The first-of-its-kind contribution will significantly enhance the NCI’s planned Data Enclave, a secure repository designed to accelerate cancer research.
Unlocking Insights from 3,000 Cancer Diagnoses
Tempus is donating de-identified tumor profiles with limited associated clinical information from over 3,000 cancer diagnoses. These anonymized data sets, derived from patients sequenced with Tempus’ xT assay, will build upon the foundation established by The Cancer Genome Atlas (TCGA) sequencing project.
Empowering Researchers with Secure Data Access
Researchers will be able to securely access and query this valuable data through the NCI Data Enclave. This innovative system utilizes an Application Programming Interface (API) to receive user queries and return anonymized, cohort-level summary results. These findings will be openly accessible to the entire cancer research community.
“Data contributions allow the cancer research community to continue to learn and advance our knowledge in cancer thereby fulfilling NCI’s mission,” said Jill Barnholtz-Sloan, PhD, Associate Director for the Informatics and Data Science Program in NCI’s Center for Biomedical Informatics and Information Technology and Senior Investigator in the NCI Division of Cancer Epidemiology and Genetics. “This data will greatly expand the genomic data resources available to the cancer research community. Datasets of this magnitude are desperately needed to have the statistical power to study rare cancers and rare subtypes of common cancers.”
